

Title (en)
IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES

Title (de)
IMMUNONKOLOGISCHE KOMBINATIONSTHERAPIE MIT IL-2-KONJUGATEN UND ANTI-EGFR-ANTIKÖRPERN

Title (fr)
POLYTHÉRAPIE PAR IMMUNO-ONCOLOGIE AVEC DES CONJUGUÉS D'IL-2 ET DES ANTICORPS ANTI-EGFR

Publication
EP 4171648 A1 20230503 (EN)

Application
EP 21746601 A 20210624

Priority

- US 202063044199 P 20200625
- US 202163196448 P 20210603
- US 2021038958 W 20210624

Abstract (en)
[origin: WO2021263026A1] Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.

IPC 8 full level
A61K 47/60 (2017.01); **A61K 39/395** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01)

CPC (source: EP IL KR)
A61K 38/2013 (2013.01 - KR); **A61K 39/3955** (2013.01 - KR); **A61K 47/60** (2017.08 - EP IL KR); **A61P 35/00** (2018.01 - EP IL KR); **C07K 16/2863** (2013.01 - EP IL KR); **A61K 2039/505** (2013.01 - EP IL KR); **A61K 2039/545** (2013.01 - EP IL KR); **A61K 2300/00** (2013.01 - EP IL KR); **C07K 2317/732** (2013.01 - EP IL KR)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
WO 2021263026 A1 20211230; AU 2021296622 A1 20230223; BR 112022026236 A2 20230117; CA 3183834 A1 20211230; CN 116209465 A 20230602; EP 4171648 A1 20230503; IL 299074 A 20230201; JP 2023531509 A 20230724; KR 20230027235 A 20230227; MX 2022016254 A 20230411; TW 202216203 A 20220501

DOCDB simple family (application)
US 2021038958 W 20210624; AU 2021296622 A 20210624; BR 112022026236 A 20210624; CA 3183834 A 20210624; CN 202180051276 A 20210624; EP 21746601 A 20210624; IL 29907422 A 20221213; JP 2022579668 A 20210624; KR 20237002291 A 20210624; MX 2022016254 A 20210624; TW 110123174 A 20210624